Wei‐En Yang
Impact in
-
- Circadian rhythm and melatonin
- Cancer Research top 5%
- Protease and Inhibitor Mechanisms
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
Papers in
-
- Cell death mechanisms and regulation 3
- RNA modifications and cancer 3
- Histone Deacetylase Inhibitors Research 2
-
- Protease and Inhibitor Mechanisms 7
- Cancer-related molecular mechanisms research 3
- Co-authors
- Shun‐Fa Yang (29 shared papers)Chiao‐Wen Lin (23 shared papers)Shih‐Chi Su (4 shared papers)Ming‐Ju Hsieh (7 shared papers)Mu‐Kuan Chen (10 shared papers)Wen‐Hung Chung (2 shared papers)Rüssel J. Reiter (1 shared paper)Chun‐Wen Su (12 shared papers)
- Journals
- International Journal of Medical Sciences (3 papers)Environmental Toxicology (2 papers)International Journal of Molecular Sciences (2 papers)PLoS ONE (2 papers)Expert Opinion on Therapeutic Targets (2 papers)
- Partner nations
- TaiwanUnited StatesSingapore
In The Last Decade
Wei‐En Yang
32 papers receiving 1.3k citations
Peers
Comparison fields: 5 of 91
- Endocrine and Autonomic Systems 169
- Cancer Research 357
- Applied Microbiology and Biotechnology 28
- Complementary and alternative medicine 88
- Oncology 230
Countries citing papers authored by Wei‐En Yang
This map shows the geographic impact of Wei‐En Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei‐En Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei‐En Yang more than expected).
Fields of papers citing papers by Wei‐En Yang
This network shows the impact of papers produced by Wei‐En Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei‐En Yang. The network helps show where Wei‐En Yang may publish in the future.
Co-authors
The 25 scholars most cited alongside Wei‐En Yang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 34 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 257 | |
| 2 | 2015 | 126 | |
| 3 | 2013 | 117 | |
| 4 | 2017 | 112 | |
| 5 | 2007 | 92 | |
| 6 | 2019 | 79 | |
| 7 | 2016 | 77 | |
| 8 | 2016 | 55 | |
| 9 | 2017 | 51 | |
| 10 | 2014 | 47 | |
| 11 | 2014 | 38 | |
| 12 | 2017 | 32 | |
| 13 | 2019 | 29 | |
| 14 | 2018 | 28 | |
| 15 | 2019 | 28 | |
| 16 | 2021 | 19 | |
| 17 | 2021 | 16 | |
| 18 | 2024 | 16 | |
| 19 | 2012 | 14 | |
| 20 | 2017 | 13 |
About Wei‐En Yang
Wei‐En Yang is a scholar working on Molecular Biology, Cancer Research, Oncology, Immunology and Organic Chemistry, having authored 34 papers that have together received 1.3k indexed citations. Recurring topics across this work include Protease and Inhibitor Mechanisms (7 papers), Peptidase Inhibition and Analysis (4 papers), Cancer-related molecular mechanisms research (3 papers), Cell death mechanisms and regulation (3 papers), RNA modifications and cancer (3 papers), Inflammation biomarkers and pathways (2 papers), Circadian rhythm and melatonin (2 papers) and Histone Deacetylase Inhibitors Research (2 papers). The work is most often cited by research in Endocrine and Autonomic Systems (169 citations), Cancer Research (357 citations), Applied Microbiology and Biotechnology (28 citations), Complementary and alternative medicine (88 citations) and Oncology (230 citations). Wei‐En Yang has collaborated with scholars based in Taiwan, United States and Singapore. Frequent co-authors include Shun‐Fa Yang, Chiao‐Wen Lin, Shih‐Chi Su, Ming‐Ju Hsieh, Mu‐Kuan Chen, Wen‐Hung Chung, Rüssel J. Reiter, Chun‐Wen Su, Pei‐Ni Chen and Wen‐Lang Fan. Their work appears in journals such as International Journal of Medical Sciences, Environmental Toxicology, International Journal of Molecular Sciences, PLoS ONE and Expert Opinion on Therapeutic Targets.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.